Results of the Prodige 2-ACCORD 12/0405 Randomized trial comparing two neoadjuvant chemo-radiotherapy (Cape 45 vs Capox 50) in patients with T3-4 rectal cancer.
Jean-Pierre GERARD, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, P.L. Etienne, V. Vendrely, T. Conroy, E. Fran?ois, C. Montoto-Grillot, for the FNCLCC - FFCD
編輯: ludongcn 作者:丁香園通訊員
以下網友留言只代表網友個人觀點，不代表網站觀點
